Palabras clave
papilomavirus humano (HPV), anticonceptivos orales, lesión precancerosa de cuello uterino, neoplasia intraepitelial cervical de grado 3
Clasificación en siicsalud
Artículos originales> Expertos del Mundo>
página www.siicsalud.com/des/des051/06n30010.htm
Especialidades
Principal: Obstetricia y Ginecología
Relacionadas: Atención Primaria, Farmacología, Medicina Familiar, Medicina Farmacéutica, Medicina Interna, Oncología
Enviar correspondencia a:
Philip Castle, Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, MD 20892-7234, Bethesda, EE.UU.
Artículo completo
(castellano)
Extensión:
+/- 3.85 páginas impresas en papel A4
Exclusivo para suscriptores/ assinantes |
COMMENTARY: HORMONAL CONTRACEPTIVES AND RISK OF CERVICAL PRECANCER
Key words
human papillomavirus (NPV), oral contraceptives, cervical precancer, cervical intraepithelial neoplasia grade 3
Full text
(english)
para suscriptores/ assinantes
|
Bibliografía del artículo
1. Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
2. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 14-9.
3. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359:1085-92.
4. Smith JS, Green J, Berrington DG, Appleby P, Peto J, Plummer M, Franceschi S, Beral V. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159-67.
5. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003; 348:489-90.
6. Castle PE, Walker JL, Schiffman M, Wheeler CM. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer 2005; 117:1007-12. |
|
